Meeting
2022 ASCO Annual Meeting
Phase 1 dose escalation study of MH048, a novel and non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies.
Authors
Guoqing Cao
Minghui Pharmaceutical (Shanghai) LTD, Shanghai, China
Guoqing Cao , Zhengming Jin , Yuhua Li , Liling Zhang , Junwei Shi , Jie Jin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04689308
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7547)
DOI
10.1200/JCO.2022.40.16_suppl.7547
Abstract #
7547
Poster Bd #
200
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2022 ASCO Annual Meeting
A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies.
First Author: Anthony Mato
Poster
2016 ASCO Annual Meeting
A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (BâNHL).
First Author: Ki Y. Chung
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe